Stocks
Entrada Therapeutics, Inc.TRDA
NASDAQHealthcareBiotechnology$4.82
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing intracellular biologics and antibody-based therapies for rare diseases. Its lead candidates target Duchenne muscular dystrophy and other neuromuscular disorders, with early clinical data drawing investor attention. The company's platform focuses on endosomal escape technology to deliver therapeutics inside cells.
52W Range: $4.11-$16.45
Congressional Interest in Entrada Therapeutics, Inc. (TRDA)
No congressional trades have been disclosed for Entrada Therapeutics, Inc. (TRDA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading TRDA?
No congressional trades found for this stock.